- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Femasys-Aktie steigt nach CE-Kennzeichnung für FemBloc zur dauerhaften Empfängnisverhütung | 2 | Investing.com Deutsch | ||
| Do | Femasys stock rises as FemBloc gets CE Mark for permanent birth control | 1 | Investing.com | ||
| 25.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 25.06. | Femasys Inc.: Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control | 163 | GlobeNewswire (Europe) | ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 17.06. | Femasys appoints Kelley Nicholas as chief commercial officer | 1 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| 17.06. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | The Analyst Verdict: Femasys In The Eyes Of 6 Experts | 2 | Benzinga.com | ||
| 11.06. | Femasys Inc.: Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations | 1 | GlobeNewswire (USA) | ||
| 02.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 30.05. | Femasys Announces $4.5 Mln Offering Through Public Sale And Private Placement Of Shares | 1 | RTTNews | ||
| 30.05. | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M | 2 | Seeking Alpha | ||
| 30.05. | Femasys Inc.: Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million | 3 | GlobeNewswire (USA) | ||
| 29.05. | Femasys plans stock offering and private placement | 1 | Investing.com | ||
| 29.05. | Femasys announces public offering, concurrent private placement | 1 | Seeking Alpha | ||
| 29.05. | Femasys plant Aktienangebot und Privatplatzierung | 2 | Investing.com Deutsch | ||
| 29.05. | Femasys Inc.: Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 23.05. | Femasys droht Delisting von der NASDAQ | 1 | Investing.com Deutsch | ||
| 23.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Jones Trading cuts Femasys stock target to $6, maintains Buy | 1 | Investing.com | ||
| 09.05. | Analyst Expectations For Femasys' Future | 2 | Benzinga.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 459,70 | +0,75 % | Intuitive Surgical stock gains as DV5 receives early CE mark approval | ||
| UNITEDHEALTH | 265,60 | -3,96 % | United-Health-Konkurrent: Kaufchance? Diese Aktie ist einfach viel zu billig! | © Foto: Google GeminiDie Aktie des US-Krankenversicherers Centene ist so günstig wie lange nicht. Das gilt nicht nur für die Aktie, sondern auch die Bewertung des Unternehmens.In der US-Krankenversicherungsbranche... ► Artikel lesen | |
| ROKU | 74,35 | +1,74 % | Roku stock rating reiterated at Market Outperform by Citizens JMP | ||
| ATOSSA THERAPEUTICS | 0,745 | +6,58 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| CENTENE | 28,680 | -40,28 % | Centene-Aktie läuft heute schlechter (46,0076 €) | Im Minus liegt aktuell der Anteilsschein von Centene . Die Aktie kostete zuletzt 53,62 US-Dollar. Ein Preisabschlag in Höhe von 43 Cent müssen derzeit die Aktionäre von Centene hinnehmen. Für das Papier... ► Artikel lesen | |
| VERU | 0,500 | -0,60 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| QUIDELORTHO | 24,600 | -3,15 % | QuidelOrtho Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
| NANO-X IMAGING | 5,370 | +5,09 % | Nano-X Imaging LTD.: Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC | Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH... ► Artikel lesen | |
| FULGENT GENETICS | 16,800 | 0,00 % | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology | ||
| LANTHEUS | 69,06 | +2,46 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,820 | +1,44 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial | [212Pb]VMT-a-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 18,400 | +3,37 % | AMN Healthcare Announces Sale Of Its Smart Square Scheduling Software | WASHINGTON (dpa-AFX) - AMN Healthcare (AMN) announced the sale of its Smart Square scheduling software to symplr. The total purchase price was $75 million, with $65 million paid at closing
and... ► Artikel lesen | |
| OMNICELL | 25,400 | 0,00 % | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery... ► Artikel lesen |
FEMASYS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,40 % bei einem Aktienkurs von 0,958 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.